Nivolumab + Relatlimab
Fixed-dose combination
This page lists brands whose active-ingredient set is exactly the combination below. It is identity information only — a fixed-dose combination is not the same product as its single ingredients, and the brand names are not interchangeable across markets.
Not medical advice. Check the pack and the exact composition before comparing products; ask a pharmacist if unsure.
Active ingredients
- Nivolumab
nivolumab - Relatlimab
relatlimab
Brands with this exact combination
| Brand | Dose | Manufacturer |
|---|---|---|
| OPDUALAGAUCAESEUUS | 12 mg / 4 mg / 240 mg / 80 mg | BRISTOL-MYERS SQUIBB CANADA |
| nivolumab + relatlimabAUES | 240 mg / 80 mg | Bristol-Myers Squibb Australia Pty Ltd |
| nivolumab and relatlimab-rmbwUS | 12 mg / 4 mg | E.R. Squibb & Sons, L.L.C. |
| Opdualag 240mg/20ml / 80mg/20ml concentrate for solution for infusion vialsGB | 240 mg / 80 mg | Bristol-Myers Squibb Pharmaceuticals Ltd |
| Nivolumab 240mg/20ml / Relatlimab 80mg/20ml solution for infusion vialsGB | 240 mg / 80 mg | Bristol-Myers Squibb Pharmaceuticals Ltd |
| relatlimab + nivolumabAU | — | — |
| OPDUALAG CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/80MGSG | — | BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD. |
| OPDUALAG nivolumab 240mg and relatlimab 80mg in 20mL concentrate solution for IV infusion vialAU | 255.6 mg / 85.2 mg | Bristol-Myers Squibb Australia Pty Ltd |
Same combination in other markets
No product with this combination is recorded in the other covered markets yet.
See warnings for these ingredients
Source & licence: built from the same regulator data as the ingredient pages (openFDA, dm+d, CIMA, COFEPRIS, PBS/TGA, Health Canada DPD, NHSA). Facts only; see the licence register.